The human mind fascinated Dr. Jeffrey Cummings long before he became an international authority on Alzheimer’s disease.

A UNLV professor is being honored for his lifetime contributions in the areas of dementia and drug development. Dr. Jeff L. Cummings is a research professor at the Kirk Kerkorian School of Medicine at UNLV.

ScholarGPS said Dr. Jeffrey L. Cummings received the title for his lifetime contributions in the areas of dementia and drug development.

Doctor Jeffrey Cummings is world-renowned in the field of Alzheimer’s research and he leads UNLV’s Center for Transformative Neuroscience. He and six other scientists published research Wednesday that looked at the potential existing drugs have for the research and treatment of Alzheimer’s, for example, drugs like rasagiline for Parkinson’s or bexarotene for cancer. It’s called repurposing.

Axsome’s expectation that AXS-05 can win market share from Rexulti is partly built on the belief that the drug candidate has a differentiated safety profile. Rexulti has a boxed warning because of an increased risk of death. There were no deaths in the AXS-05 trials. Jeffrey Cummings, a research professor at the University of Nevada, Las Vegas, discussed what may happen if AXS-05 avoids a boxed warning.

Axsome Therapeutics said on Monday it would seek marketing approval next year for its oral drug to treat agitation in patients with Alzheimer’s disease, after it succeeded in three out of four late-stage studies.

Today, Axsome will host a conference call and webcast to discuss these topline results. Dr. Jeffrey Cummings, Vice Chair of Research at UNLV Department of Brain Health, will join the call and be available for questions.

Cleveland Clinic Genome Center researchers have unraveled how microglia, which perform key neuroprotective activities, also can transform and drive harmful processes such as inflammation in Alzheimer’s disease.